

(51) International Patent Classification:
A61K 39/085 (2006.01)(21) International Application Number:
PCT/US2013/068385(22) International Filing Date:
5 November 2013 (05.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/723,128 6 November 2012 (06.11.2012) US

(71) Applicant: MEDIMMUNE, LLC [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors: SELLMAN, Bret; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). TKACZYK, Christine; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). HAMILTON, Melissa; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). HUA, Lei; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).

(74) Agents: MUKHERJEE, Mita et al.; MEDIMMUNE, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS OF TREATING *S. AUREUS*-ASSOCIATED DISEASES

FIG. 1



(57) Abstract: The present invention provides for methods of preventing and/or treating *S. aureus*-associated bacteremia and sepsis, and methods for preventing and/or treating *S. aureus*-associated pneumonia in immunocompromised patients using anti-*S. aureus* alpha-toxin (antiAT) antibodies. Also provided are methods of reducing *S. aureus* bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-*S. aureus* alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing *S. aureus* bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-*S. aureus* alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of *S. aureus*-associated pneumonia in an immunocompromised mammalian subject.



Published:

— *with international search report (Art. 21(3))*